Market leader atai Life Sciences has been in the news lately. Yesterday the company launched a new philanthropic program, and last week they announced the launch of PsyProtix, a precision psychiatry approach for depression.
Now we have the news of atai getting analyst coverage from H.C. Wainwright. The analyst has come out with a very positive Buy rating and an extremely bullish $40 price target. The report states atai’s broad pipeline of 11 companies and development programs as the main reason for the favorable projection.
Keeping in mind that analysts don’t have crystal balls and that these reports should be taken with some grains of salt, when added to the list of other projections it begins to paint a less pixelated picture.
Other recent reports include: a $35 target and Buy rating from Berenberg; Cantor Fitzgerald giving a 12-month price target of $45; an Outperform Rating and $25 target from Credit Suisse; and a $26 projection and Buy ratings from both Aegis Capital and Citigroup.
Here’s a snapshot of H.C. Wainwright’s coverage of atai Life Sciences.
Interested in more analyst news? Check out Cybin Gets More Positive Coverage from Major Analyst and Compass Pathways Receives Positive Analyst Coverage
